Criteria Used by Health Professionals on the Selection of Allergen Immunotherapy in Real Clinical Practice

Allergen Immunotherapy Clinical Trial

— CHOICE  

Official title:

Criteria Used by Health Professionals on the Selection of Allergen Immunotherapy in Real Clinical Practice: an International E-survey

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04038268
• Other study ID #: RECHMPL19_0361
• Status: Completed
• Start date: September 1, 2019
• Est. completion date: September 30, 2020

Study information

• Verified date: December 2020
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background : Allergen Immunotherapy (AIT) is the only etiological treatment for allergic respiratory diseases. In order to improve the competence on the use of AIT, it is important to extend the investigator's knowledge on its use in routine clinical practice, outside the experimental setting of clinical trials, in real life population of patients receiving AIT.

Objective: To evaluate the clinical criteria used by treating clinicians and by the patients themselves, when establishing AIT as treatment in a patient with respiratory disease caused by an IgE-dependent-hypersensitivity to aeroallergens Methods: In 6 country (Denmark, France, Germany, Norway, Spain & Sweden), the national coordinator will be directly responsible for selection of Survey Doctor's participants (Investigators).

During 12 months:

• Firstly, each investigator will complete the Survey Doctor, online, on SurveyMonkey platform to explain what are the key drivers in Allergen Immunotherapy (AIT) selection (Doctors' Questionnaire, DQ).

• On the other hand, at each AIT prescription to a patient, doctors will complete the Survey Patient, on the same platform, to explain how and why they have chosen this type of AIT (Patients' Questionnaire, PQ).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: September 30, 2020
• Est. primary completion date: September 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years and older

Eligibility

Inclusion criteria:

• Patients with IgE mediated respiratory allergy

• Patients who will initiate any type of aeroallergen AIT according to real life clinical standards of practice

• Any type of aeroallergen for AIT will be included : pollen, house dust mite, animal, dander, moulds

• Patient who is under the care of the Doctor participating in the survey

Exclusion criteria:

• Patients who refuse to give their informed consent

• Food immunotherapy

• Venom Immunotherapy

Related Conditions & MeSH terms

• Allergen Immunotherapy

Locations

Country	Name	City	State
France	Uhmontpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical criteria in AIT	Clinical criteria used by treating clinicians and by the patients themselves, when establishing AIT as treatment in a patient with respiratory disease. These are called "drivers of prescription".; caused by an IgE-dependent-hypersensitivity to aeroallergens Among the different criteria selected by participants, order of priority of AIT drivers will be established	1 day